Responses
Clinical/translational cancer immunotherapy
Original research
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
Compose a Response to This Article
Other responses
No responses have been published for this article.
